Thrombin inhibitors

A compound of the formula

• 29
• or a pharmaceutically acceptable salt thereof, wherein
• R1 is selected from the group consisting of hydrogen, halogen, cyano, C1-4 alkyl, cyclo C3-7 alkyl, and CF3;
• A is CH or N;
• n is 0 or 1;
• R2 is hydrogen or —C(R7)(R8)C(R9)(R10)R11, wherein
• R7 and R8 are independently selected from the group consisting of hydrogen, halogen and C1-4 alkyl unsubstituted or substituted with halogen, 0R12, N(R12)2, COOR12, CON(R12)2, aryl or a heterocyclic ring, wherein R12 is independently selected from the group consisting of hydrogen and C1-4 alkyl,
• R9 and R10 are independently selected from the group consisting of hydrogen, halogen, and C1-4 alkyl, and
• R11 is aryl, C1-4 alkyl, C3-7 cycloalkyl, or heterocycle;
• R13 and R14 are independently selected from the group consisting of hydrogen and C1-2 alkyl unsubstituted or substituted with OR15 or COOR15, wherein R15 is hydrogen or C1-4 alkyl;
• R15 and R16 are independently selected from the group consisting of hydrogen, halogen and C1-4 alkyl;
• 30
• R3 is selected from the group consisting of
• 1) hydrogen,
• 2) halogen,
• 3) hydroxy,
• 4) C1-4 alkyl,
• 5) C1-4 alkoxy,
• 6) cyano,
• 7) —OCF3,
• 8) —OCHF2,
• 9) —OCH2CF3,
• 10) —C(R23)(R24)C(R25)(R26)N(R27)(R28) or —C(R23)(R24)N(R27)(R28) wherein
• R23 and R24 are independently selected from the group consisting of
• a) hydrogen,
• b) F,
• c) C1-4 alkyl,
• d) —CF3,
• e) —CHF2,
• f) C3-7 cycloalkyl,
• or R23 and R24 together form a 3-7 membered carbocyclic ring,
• R25 and R26 are independently selected from the group consisting of
• a) hydrogen,
• b) C1-4 alkyl
• c) —CF3,
• d) —CHF2,
• e) —CH2OH,
• f) C3-6 cycloalkyl,
• or R25 and R26 together form a 3-7 membered carbocyclic ring,
• R27 and R28 are independently selected from the group consisting of
• a) hydrogen,
• b) C1-6 alkyl, unsubstituted or substituted with —OH, C3-7 cycloalkyl, or —C(O)OR31, wherein R31 is selected from the group consisting of hydrogen and C1-6 alkyl, and
• c) C3-7 cycloalkyl,
• or R27 and R28 are joined to form a 4-7 membered heterocyclic ring which is unsubstituted or substituted with hydroxyl or halogen,
• 11) —SR17,
• 12) —SOR17,
• 13) —SO2R17,
• 14) —OR18,
• 15) —SR18,
• 16) —NHR18,
• 31
• wherein
• R17 is C1-4 alkyl unsubstituted or substituted with —C(CH3)2NH2, —C(CH3)2OH, —C(CH3)2NHCOCF3, or CF3, and
• R18 is phenyl unsubstituted or substituted with one or more of C1-4 alkyl, C1-4 alkoxy, halogen, hydroxy, COOH, CONH2, CH2OH or COOR19, wherein R19 is C1-4 alkyl;
• R4 is selected from the group consisting of
• 1) hydrogen,
• 2) halogen,
• 3) hydroxy,
• 4) C1-4 alkyl,
• 5) C1-4 alkoxy,
• 6) cyano,
• 7) —OCF3,
• 8) —OCHF2, and
• 9) —OCH2CF3.